Dendritic cell subsets in type 1 diabetes: friend or foe?
Type 1 diabetes (T1D) is a T cell mediated autoimmune disease characterized by immune mediated destruction of the insulin producing β cells in the islets of Langerhans. Dendritic cells (DC) have been implicated in the pathogenesis of T1D and are also used as immunotherapeutic agents. Plasmacytoid (p...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2013-12-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fimmu.2013.00415/full |
id |
doaj-bc82c4d0d479496ba395ca55b246d6b4 |
---|---|
record_format |
Article |
spelling |
doaj-bc82c4d0d479496ba395ca55b246d6b42020-11-24T22:57:08ZengFrontiers Media S.A.Frontiers in Immunology1664-32242013-12-01410.3389/fimmu.2013.0041571010Dendritic cell subsets in type 1 diabetes: friend or foe?Penelope Anne Morel0University of PittsburghType 1 diabetes (T1D) is a T cell mediated autoimmune disease characterized by immune mediated destruction of the insulin producing β cells in the islets of Langerhans. Dendritic cells (DC) have been implicated in the pathogenesis of T1D and are also used as immunotherapeutic agents. Plasmacytoid (p)DC have been shown to have both protective and pathogenic effects and a newly described merocytic DC population has been shown to break tolerance in the mouse model of T1D, the non obese diabetic (NOD) mouse. We have used DC populations to prevent the onset of T1D in NOD mice and clinical trials of DC therapy in T1D diabetes have been initiated. In this review we will critically examine the recent published literature on the role of DC subsets in the induction and regulation of the autoimmune response in T1D.http://journal.frontiersin.org/Journal/10.3389/fimmu.2013.00415/fullAutoimmunityDendritic CellstolerancetherapyT regulatory cellstype 1 diabetes |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Penelope Anne Morel |
spellingShingle |
Penelope Anne Morel Dendritic cell subsets in type 1 diabetes: friend or foe? Frontiers in Immunology Autoimmunity Dendritic Cells tolerance therapy T regulatory cells type 1 diabetes |
author_facet |
Penelope Anne Morel |
author_sort |
Penelope Anne Morel |
title |
Dendritic cell subsets in type 1 diabetes: friend or foe? |
title_short |
Dendritic cell subsets in type 1 diabetes: friend or foe? |
title_full |
Dendritic cell subsets in type 1 diabetes: friend or foe? |
title_fullStr |
Dendritic cell subsets in type 1 diabetes: friend or foe? |
title_full_unstemmed |
Dendritic cell subsets in type 1 diabetes: friend or foe? |
title_sort |
dendritic cell subsets in type 1 diabetes: friend or foe? |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2013-12-01 |
description |
Type 1 diabetes (T1D) is a T cell mediated autoimmune disease characterized by immune mediated destruction of the insulin producing β cells in the islets of Langerhans. Dendritic cells (DC) have been implicated in the pathogenesis of T1D and are also used as immunotherapeutic agents. Plasmacytoid (p)DC have been shown to have both protective and pathogenic effects and a newly described merocytic DC population has been shown to break tolerance in the mouse model of T1D, the non obese diabetic (NOD) mouse. We have used DC populations to prevent the onset of T1D in NOD mice and clinical trials of DC therapy in T1D diabetes have been initiated. In this review we will critically examine the recent published literature on the role of DC subsets in the induction and regulation of the autoimmune response in T1D. |
topic |
Autoimmunity Dendritic Cells tolerance therapy T regulatory cells type 1 diabetes |
url |
http://journal.frontiersin.org/Journal/10.3389/fimmu.2013.00415/full |
work_keys_str_mv |
AT penelopeannemorel dendriticcellsubsetsintype1diabetesfriendorfoe |
_version_ |
1725651836369633280 |